EMEA-002149-PIP01-17

Key facts

Active substance
DaxibotulinumtoxinA
Therapeutic area
Other
Decision number
P/0220/2017
PIP number
EMEA-002149-PIP01-17
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of glabellar lines
Route(s) of administration
Intramuscular use
Contact for public enquiries
Revance Therapeutics Inc
United States
Tel. +1 5107423559
E-mail: lmcbride@revance.com
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating